Expert Review of Anticancer Therapy, Volume 22, Issue 12 (2022)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Expert Review of Anticancer Therapy, Volume 22, Issue 12 (2022)

See all volumes and issues
Vol 24, 2024 Vol 23, 2023 Volume 22, 2022 Vol 21, 2021 Vol 20, 2020 Vol 19, 2019 Vol 18, 2018 Vol 17, 2017 Vol 16, 2016 Vol 15, 2015 Vol 14, 2014 Vol 13, 2013 Vol 12, 2012 Vol 11, 2011 Vol 10, 2010 Vol 9, 2009 Vol 8, 2008 Vol 7, 2007 Vol 6, 2006 Vol 5, 2005 Vol 4, 2004 Vol 3, 2003 Vol 2, 2002 Vol 1, 2001
Download citations Download PDFs Download issue

Editorial

Editorial
Why has targeting EGFR aberrations in glioblastoma therapy had limited success?
Sani H. Kizilbash
Pages: 1261-1263
Published online: 14 Nov 2022
First Page PreviewforWhy has targeting EGFR aberrations in glioblastoma therapy had limited success? | Full Text | References | PDF (146.7 KB) | EPUB
  • 1289 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access

Drug Profile

Article
Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion
Michael H. Storandt, Zhaohui Jin & Amit Mahipal
Pages: 1265-1274
Published online: 23 Nov 2022
AbstractforPemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion | Full Text | References | PDF (1.3 MB) | EPUB
  • 440 Views
  • 1 CrossRef citations
  • 0Altmetric

Review

Review
Hot topics in renal cancer pathology: implications for clinical management
Alessia Cimadamore, Anna Caliò, Laura Marandino, Stefano Marletta, Carmine Franzese, Luigi Schips, Daniele Amparore, Riccardo Bertolo, Stijn Muselaers, Selcuk Erdem, Alexandre Ingels, Nicola Pavan, Angela Pecoraro, Önder Kara, Eduard Roussel, Umberto Carbonara, Riccardo Campi, Michele Marchioni & on behalf of EAU-YAU Renal Cancer Working Group.
Pages: 1275-1287
Published online: 08 Dec 2022
AbstractforHot topics in renal cancer pathology: implications for clinical management | Full Text | References | PDF (11.4 MB) | EPUB
  • 259 Views
  • 1 CrossRef citations
  • 0Altmetric
Review
Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer
Shimoli V. Barot, Erin Roesch & Jame Abraham
Pages: 1289-1299
Published online: 17 Nov 2022
AbstractforOptimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer | Full Text | References | PDF (1.1 MB) | EPUB
  • 368 Views
  • 0 CrossRef citations
  • 0Altmetric
Review
Management of breast cancer diagnosed during pregnancy: global perspectives
Jyoti Bajpai, Rima Pathak, T.S. Shylasree & Hope S. Rugo
Pages: 1301-1308
Published online: 08 Dec 2022
AbstractforManagement of breast cancer diagnosed during pregnancy: global perspectives | Full Text | References | PDF (1.7 MB) | EPUB
  • 247 Views
  • 1 CrossRef citations
  • 0Altmetric
Review
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?
Amir Imran Faisal Hamdi, Soon Hin How, Mohammad Kaisarul Islam, Jonathan Chee Woei Lim & Johnson Stanslas
Pages: 1309-1323
Published online: 24 Nov 2022
AbstractforAdaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant? | Full Text | References | PDF (3.2 MB) | EPUB
  • 113 Views
  • 0 CrossRef citations
  • 0Altmetric
Review
The evolving therapeutic landscape of antibody–drug conjugates in breast cancer
Nan Chen, Elena Michaels, Frederick Howard & Rita Nanda
Pages: 1325-1331
Published online: 21 Nov 2022
AbstractforThe evolving therapeutic landscape of antibody–drug conjugates in breast cancer | Full Text | References | PDF (229.7 KB) | EPUB
  • 296 Views
  • 0 CrossRef citations
  • 0Altmetric

Meta-analysis

Chemotherapy plus panitumumab/cetuximab versus chemotherapy plus bevacizumab in wild-type KRAS/RAS metastatic colorectal cancer: a meta-analysis
Chengren Zhang, Lili Liu, Yaochun Lv, Jingjing Li, Cong Cao, Jiyong Lu, Shuai Wang, Binbin Du & Xiongfei Yang
Pages: 1333-1347
Published online: 22 Nov 2022
AbstractforChemotherapy plus panitumumab/cetuximab versus chemotherapy plus bevacizumab in wild-type KRAS/RAS metastatic colorectal cancer: a meta-analysis | Full Text | References | PDF (7.7 MB) | EPUB | Supplemental
  • 229 Views
  • 0 CrossRef citations
  • 0Altmetric

Original Research

Article
Mucosa-associated lymphoid tissue lymphoma in thymus: a SEER analysis
Meng-Xin Zhou, Ye-Ye Chen, Lei Liu, Gui-Ge Wang, Jia-Qi Zhang, Ke Zhao & Shan-Qing Li
Pages: 1349-1355
Published online: 14 Nov 2022
AbstractforMucosa-associated lymphoid tissue lymphoma in thymus: a SEER analysis | Full Text | References | PDF (1 MB) | EPUB
  • 157 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis
Qingfeng Ye, Jundan Wang, Da Xu, Yu Liu, Dimei Zhang, Jufeng Ye & Hua Li
Pages: 1357-1369
Published online: 18 Nov 2022
AbstractforDiagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis | Full Text | References | PDF (9.1 MB) | EPUB
  • 257 Views
  • 3 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

The new life of ibrutinib therapy in CLL: enhancing personalized approaches
Stefano Molica et al.
Editorial | Published online: 12 Jul 2024
Free Access
Immune-related adverse events associated with Mogamulizumab: a comprehensive review of the literature
Genevieve S. Silva et al.
Review Article | Published online: 11 Jul 2024
Elevated DKK1 expression: A promising prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma
Waseem Jerjes
Letter to the Editor | Published online: 11 Jul 2024
Free Access
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC
Pierre Peterlin et al.
Article | Published online: 10 Jul 2024
Open Access
View all latest articles